CLDX

Celldex Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 0/10
  • Value↓ 0/10
Celldex Therapeutics sales and earnings growth
CLDX Growth
Low
  • Revenue Y/Y↓ -77.99%
  • EPS Y/Y↓ -59.18%
  • FCF Y/Y↓ -33.79%
Celldex Therapeutics gross and profit margin trends
CLDX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -16748.00%
  • ROIC 5Y↓ -36.64%
Celldex Therapeutics net debt vs free cash flow
CLDX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Celldex Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗